PARIS--(BUSINESS WIRE)--Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful ...
LIPHOOK, United Kingdom, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Lumi Global, a global leader in technology-driven governance and voting solutions, today announced the acquisition of Eligo, Italy’s leading ...
Khosla Ventures and Seventure Partners have driven Eligo Bioscience to a $20 million (€17 million) series A. The round equips Eligo to move its lead CRISPR-enabled, bacteria-killing candidate toward ...
Covers Eligo unique ability to engineer and functionalize skin microbiome resident bacteria, Cutibacterium acnes Supports Eligo's lead program in moderate-to-severe acne vulgaris with POC clinical ...
In-vivo data in disease model further supports development of Eligo's CRISPR-Cas antimicrobial strategies and its Eligobiotics® platform Phase 1 trial for EB003 lead candidate expected to commence in ...
MIT spin-off Eligo Bioscience has raised 2 million euros in Series A funding. Seventure led the round. Based in Paris, Eligo is an antibiotics maker. Paris, France – 09 July 2015 – Seventure, one of ...
PARIS, Jan. 11, 2021 /PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing ...
(RTTNews) - Eligo Bioscience SA has reached a research and option agreement with GlaxoSmithKline (GSK) aimed at advancing Eligobiotics for the treatment or prevention of acne vulgaris with a ...
Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback